

In the Claims:

For the Examiner's convenience, Applicants present all pending claims with status indicators in compliance with the practice guidelines for making amendments under 37 C.F.R. §1.121(c)(1).

Please cancel claims 24-29, 31-34, 36-41, 44-46, 49 and 52-53 as follows:

Claims 1-34 (CANCELLED)

35. (PREVIOUSLY PRESENTED) A method for selectively destroying a cell expressing the polypeptide of Figure 2 (SEQ ID NO: 2) comprising contacting said cell with an amount of immunoconjugate that can destroy said cell, wherein said immunoconjugate comprises an isolated antibody, or fragment thereof, conjugated to a cytotoxic agent, and wherein said isolated antibody, or fragment thereof, specifically binds to a polypeptide sequence selected from the group consisting of:

- (a) amino acid 28 to amino acid 46 of SEQ ID NO: 2;
- (b) amino acid 77 to amino acid 91 of SEQ ID NO: 2;
- (c) amino acid 188 to amino acid 210 of SEQ ID NO: 2; and
- (d) amino acid 263 to amino acid 274 of SEQ ID NO: 2.

Claims 36-46 (CANCELLED)

47. (PREVIOUSLY PRESENTED) The method of claim 35, wherein the cytotoxic agent is selected from the group consisting of ricin, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphtheria toxin, *Pseudomonas* exotoxin (PE) A, PE40, ricin, abrin, glucocorticoid and